Loading...
Loading...
- Balchem Corp BCPC reported third-quarter FY21 sales growth of 13% year-on-year, to $197.87 million, beating the analyst consensus of $196.13 million.
- Sales from Human Nutrition and Health segment rose 7.3% Y/Y to $111.2 million, Animal Nutrition and Health increased 21.2% to $56.2 million, and Specialty Products grew 20% to $27.6 million.
- The gross margin increased 8.1% Y/Y to $60.9 million, with the margin contracting 139 basis points 30.7%.
- The operating margin was 16.4%, and operating income for the quarter rose 12% to $32.5 million.
- Balchem held $90 million in cash and equivalents as of September 30, 2021. Cash flow from operations totaled $39.6 million with a free cash flow of $31.1 million.
- Adjusted EPS of $0.92 beat the analyst consensus of $0.90.
- Adjusted EBITDA was $48.3 million, an increase of 8.8% Y/Y.
- "We expect these macro-economic challenges, including global supply chain disruptions and input cost inflation, to continue to accelerate into the fourth quarter and next year, and mitigating these impacts will remain a key focus for the Balchem team," said Ted Harris, Chairman, CEO, and President of Balchem.
- Price Action: BCPC shares are trading lower by 0.39% at $152.58 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in